Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and Y chromosomal constitution with different genetic etiologies.
Y chromosome
children
disorders of sex development
gonadal biopsy
gonadal tumor
gonadectomy
phenotypic female
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
01
2022
accepted:
27
06
2022
entrez:
8
8
2022
pubmed:
9
8
2022
medline:
9
8
2022
Statut:
epublish
Résumé
This retrospective study sought to investigate the risk and proportion of gonadal neoplasms in phenotypic female pediatric patients with DSD and the presence of the Y chromosome and different genetic backgrounds in a single Chinese center. From January 2012 to December 2020, pediatric and adolescent patients with DSD and the presence of the Y chromosome who had unambiguous female genitalia and underwent bilateral gonadectomy or gonadal biopsy were included in this study. Patients' demographics, karyotype, laboratory test results, gross pathology, and histology of gonadal tissue were all collected. The patients were divided into three groups based on their different genetic backgrounds, and the percentage of gonadal tumors was calculated to assess the risk of gonadal tumor and malignancy by etiology. A total of 22 patients with DSD and an unambiguous female phenotype with a Y chromosome were recruited. The mean age was 10.91 ± 4.99 years (9 months to 19 years). Gonadal neoplasia was confirmed in six (27.3%) cases by pathological examination of surgical gonadal tissue samples. Among 44 gonadal samples from these 22 patients, the following were identified: five gonadoblastomas, three dysgerminomas, and two Leydig cell tumors. The youngest patient with a tumor was a 2-year-old girl with 46,XY complete gonadal dysgenesis (46,XY CGD or Swyer syndrome) and bilateral gonadoblastoma. Patients with 46,XY complete gonadal dysgenesis (4/6; 66.7%) had the highest tumor occurrence rate. Among 10 patients with Turner syndrome with the presence of the Y chromosome, only one patient was diagnosed with a gonadal tumor. Leydig cell tumor was diagnosed in only one of six patients with 46,XY androgen synthesis/action disorders. Pediatric patients with 46,XY complete gonadal dysgenesis had a significantly increased risk of developing gonadal tumors and underwent prophylactic gonadectomy as soon as the diagnosis was confirmed, whereas those with Turner syndrome with Y chromosome and 46,XY androgen synthesis/action disorders had a relatively low risk. In view of the limited number of patients, a large multicenter study with close follow-ups is needed to support these conclusions.
Identifiants
pubmed: 35935368
doi: 10.3389/fped.2022.856128
pmc: PMC9353051
doi:
Types de publication
Journal Article
Langues
eng
Pagination
856128Informations de copyright
Copyright © 2022 Lu, Luo and Wang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Endocrinol (Oxf). 1990 Apr;32(4):519-33
pubmed: 2189603
J Clin Oncol. 2019 Jun 1;37(16):1412-1423
pubmed: 30875280
Zhonghua Er Ke Za Zhi. 2016 Aug;54(8):619-22
pubmed: 27510877
J Pediatr Adolesc Gynecol. 2020 Feb;33(1):10-14
pubmed: 31465855
Lancet Oncol. 2008 Mar;9(3):239-46
pubmed: 18282803
Int J Pediatr Endocrinol. 2014;2014(1):4
pubmed: 24731683
J Pediatr Urol. 2016 Dec;12(6):411-416
pubmed: 27769830
PLoS One. 2012;7(7):e40858
pubmed: 22815844
J Pediatr Surg. 1988 Mar;23(3):270-1
pubmed: 3357146
Transl Androl Urol. 2016 Oct;5(5):794-798
pubmed: 27785439
Arch Dis Child. 2006 Jul;91(7):554-63
pubmed: 16624884
J Clin Endocrinol Metab. 2006 Oct;91(10):3897-902
pubmed: 16849410
Pediatr Blood Cancer. 2018 Apr;65(4):
pubmed: 29286555
Orphanet J Rare Dis. 2021 Aug 30;16(1):370
pubmed: 34461970
J Clin Endocrinol Metab. 2000 Sep;85(9):3199-202
pubmed: 10999808
Arch Pathol Lab Med. 2012 Apr;136(4):435-46
pubmed: 22458906
Clin Pediatr Endocrinol. 2014 Jul;23(3):93-7
pubmed: 25110393
Clin Endocrinol (Oxf). 2017 Aug;87(2):136-140
pubmed: 28493277
BMC Cancer. 2006 Jun 09;6:154
pubmed: 16762081
J Endocr Soc. 2022 Jan 29;6(3):bvac011
pubmed: 35178494
Mol Genet Metab. 2001 Mar;72(3):254-9
pubmed: 11243732
Hum Reprod. 2014 Jul;29(7):1413-9
pubmed: 24826988
BJU Int. 2012 Dec;110(11 Pt C):E958-65
pubmed: 22540217
J Clin Endocrinol Metab. 2006 Jun;91(6):2404-13
pubmed: 16608895
Am J Med Genet C Semin Med Genet. 2017 Jun;175(2):304-314
pubmed: 28544305
J Clin Endocrinol Metab. 2000 Mar;85(3):1226-31
pubmed: 10720067
J Pediatr Endocrinol Metab. 2017 Nov 27;30(12):1285-1291
pubmed: 29176021
Eur Urol. 2015 Apr;67(4):692-701
pubmed: 25240975
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
J Clin Endocrinol Metab. 2002 Jan;87(1):29-32
pubmed: 11788616
Br J Cancer. 1996 May;73(9):1156-9
pubmed: 8624281
Mod Pathol. 2005 Mar;18(3):439-45
pubmed: 15475933
Pediatr Blood Cancer. 2020 Apr;67(4):e28169
pubmed: 32020769
Zhonghua Nei Ke Za Zhi. 2021 Sep 1;60(9):827-830
pubmed: 34445820
Gynecol Endocrinol. 2016;32(4):338-41
pubmed: 26608236
J Pediatr Endocrinol Metab. 2015 Sep;28(9-10):1019-27
pubmed: 25879315
J Pediatr Urol. 2016 Oct;12(5):283.e1-283.e7
pubmed: 27052295
Clin Endocrinol (Oxf). 2017 Apr;86(4):621-627
pubmed: 27862157
Pediatr Dev Pathol. 2005 Mar-Apr;8(2):197-203
pubmed: 15747103
BMC Med Genet. 2012 Nov 16;13:108
pubmed: 23157850
J Clin Endocrinol Metab. 1999 May;84(5):1628-32
pubmed: 10323391
J Paediatr Child Health. 1999 Apr;35(2):210-3
pubmed: 10365364